Search - tctmd.com

Displaying 201 - 220 of 366

Sort: Relevancy | Date

Presentation EuroPCR 2018

Real World Outcomes of TAVR with the SAPIEN-3 Valve in Intermediate Risk Patients: Comparison of Data from the TVT Registry with PARTNER S3 Studies

Presenter: E. Murat Tuzcu

May 25, 2018

News Conference News EuroPCR 2018

Real-World Sapien 3 Results Match Trial Experience in Intermediate-Risk Patients

Caitlin E. Cox

May 25, 2018

News Industry News

Edwards Completes Enrollment In PARTNER 3 Low-Risk CT Sub-Study, Updates Timeline For SAPIEN 3 Ultra System Launch In Europe

March 22, 2018

News Conference News CRT 2018

Early Low-Risk TAVR Data Reassure, but Durability Questions Remain

Michael O'Riordan

March 05, 2018

News Industry News

Edwards' Self-Expanding Transcatheter Heart Valve Receives CE Mark

February 20, 2018

News Daily News

TAVR Outcomes Worse When the Right Ventricle Is Dysfunctional

Todd Neale

February 16, 2018

News Daily News

Meta-analysis Raises ‘Red Flag’ on TAVR in Low-Risk Patients

L.A. McKeown

February 07, 2018

News Daily News

Low Rate of Bailout Emergency Surgery During TAVR, but Caution Still Needed

Michael O'Riordan

January 10, 2018

News Daily News

Sex Differences Diminish With Third-Generation TAVR Device

L.A. McKeown

January 05, 2018

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Conference News AHA 2017

More Support for TMVR After Failed Mitral Bioprostheses

Yael L. Maxwell

November 23, 2017

News Opinion Editor's Corner TCT 2017

My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self

Shelley Wood

November 22, 2017

News Conference News TCT 2017

Experts Debate: Should Cerebral Protection Be Used for All TAVRs?

Todd Neale

November 09, 2017

News Conference News TCT 2017

A-fib Signals Worse Prognosis After Aortic Valve Replacement in Intermediate-Risk Patients

Todd Neale

November 08, 2017

Presentation TCT 2017

Hemodynamic Trends on Serial Echocardiograms after TAVR: Comprehensive 5-Year Analyses From PARTNER

Presenter: Pamela S. Douglas

November 01, 2017

News Conference News TCT 2017

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

Yael L. Maxwell

October 31, 2017

Presentation TCT 2017

Important Clinical Lessons From the VIVID Registry and the PARTNER Experience

Presenter: John G. Webb

October 30, 2017

Presentation TCT 2017

The PARTNER 3 Low-risk Trial

Presenter: Michael J. Mack

October 30, 2017

Presentation TCT 2017

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

Presenter: Michael J. Reardon

October 30, 2017

News Conference News TCT 2017

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

Shelley Wood

October 20, 2017

Advertisement

Real World Outcomes of TAVR with the SAPIEN-3 Valve in Intermediate Risk Patients: Comparison of Data from the TVT Registry with PARTNER S3 Studies

Real-World Sapien 3 Results Match Trial Experience in Intermediate-Risk Patients

Edwards Completes Enrollment In PARTNER 3 Low-Risk CT Sub-Study, Updates Timeline For SAPIEN 3 Ultra System Launch In Europe

Early Low-Risk TAVR Data Reassure, but Durability Questions Remain

Edwards' Self-Expanding Transcatheter Heart Valve Receives CE Mark

TAVR Outcomes Worse When the Right Ventricle Is Dysfunctional

Meta-analysis Raises ‘Red Flag’ on TAVR in Low-Risk Patients

Low Rate of Bailout Emergency Surgery During TAVR, but Caution Still Needed

Sex Differences Diminish With Third-Generation TAVR Device

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

More Support for TMVR After Failed Mitral Bioprostheses

My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self

Experts Debate: Should Cerebral Protection Be Used for All TAVRs?

A-fib Signals Worse Prognosis After Aortic Valve Replacement in Intermediate-Risk Patients

Hemodynamic Trends on Serial Echocardiograms after TAVR: Comprehensive 5-Year Analyses From PARTNER

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

Important Clinical Lessons From the VIVID Registry and the PARTNER Experience

The PARTNER 3 Low-risk Trial

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content